CRYOSITE LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.85 AUD | -.--% |
|
+4.94% | +40.50% |
| 22/02 | Cryosite Limited Announces Board Changes | CI |
| 22/02 | Cryosite Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
| Sales 2022 | 11.76M 7.67M 641M | Sales 2023 | 11.94M 7.79M 650M | Capitalization | 30.51M 19.9M 1.66B |
|---|---|---|---|---|---|
| Net income 2022 | 1M 652K 54.49M | Net income 2023 | 1M 652K 54.49M | EV / Sales 2022 | 2.23 x |
| Net cash position 2022 | 4.49M 2.93M 245M | Net cash position 2023 | 3.12M 2.04M 170M | EV / Sales 2023 | 2.29 x |
| P/E ratio 2022 |
22.6
x | P/E ratio 2023 |
21.7
x | Employees | 25 |
| Yield 2022 |
1.59% | Yield 2023 |
2.4% | Free-Float | 18.83% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 week | +4.94% | ||
| Current month | +23.19% | ||
| 1 month | +23.19% | ||
| 3 months | +17.24% | ||
| 6 months | +31.78% | ||
| Current year | +40.50% |
1 week
0.83
0.87
1 month
0.640.87
Current year
0.600.87
1 year
0.510.87
3 years
0.270.87
5 years
0.030.87
10 years
0.030.87
| Managers | Title | Age | Since |
|---|---|---|---|
John Hogg
CEO | Chief Executive Officer | - | 01/18/01 |
Jane Hao
DFI | Director of Finance/CFO | - | 08/21/08 |
Dray Andrea
SEC | Corporate Secretary | - | 18/23/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 21/11/21 | |
Mark Kerr
CHM | Chairman | - | 08/12 |
John Hogg
CEO | Chief Executive Officer | - | 01/18/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/24/30 | 0.85 | -.--% | 2,026 |
| 29/24/29 | 0.85 | -.--% | 1,050 |
| 26/24/26 | 0.85 | -2.30% | 61,196 |
| 24/24/24 | 0.87 | +4.82% | 46,686 |
| 23/24/23 | 0.83 | +2.47% | 17,000 |
Delayed Quote Australian S.E., April 30, 2024 at 05:32 am IST
More quotes
Cryosite Limited is engaged in providing outsourced clinical trials depot services. The Company manages the entire clinical trial supply chain from importation, receipt, specialized ambient, cold, frozen, and liquid nitrogen storage for temperature-sensitive products, distribution and reverse logistics management. Its segments include Clinical trials and biological services logistics and Cord Blood and tissue storage. The Clinical trials and biological services logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, biological services and cell gene therapies depot services. Cord Blood and tissue storage segment provides storage of cord blood and tissue samples. Its facilities are purpose-built to store a range of biological materials, including Cell Banks (MCB, WCB), Mesenchymal Stromal Cell (MSC) Therapies, Tumour-Infiltrating Lymphocyte Therapies and others.
Calendar
23/08/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +40.50% | 26.94M | |
| -28.69% | 85.35B | |
| +14.32% | 81.95B | |
| +9.37% | 28.99B | |
| -11.43% | 16.98B | |
| -0.36% | 16.85B | |
| -0.24% | 15.35B | |
| +4.32% | 12.42B | |
| +33.40% | 12.19B | |
| -31.40% | 11.89B |
- Stock Market
- Equities
- CTE Stock
